Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292960 | 1.00 | ATM (0.36) | ATMSPHK2SPHK1SMN1; SMN2RAB9A | |
| SCHEMBL10292815 | 0.99 | ATM (0.36) | ATMSPHK2SPHK1SMN1; SMN2RAB9A | |
| SCHEMBL10292959 | 0.97 | RAB9A (0.37) | ATMSMN1; SMN2RAB9ALMNAALDH1A1 | |
| SCHEMBL10261621 | 0.92 | ATM (0.36) | ATMSPHK2SPHK1SMN1; SMN2RAB9A | |
| SCHEMBL10261625 | 0.92 | ATM (0.36) | ATMSPHK2SPHK1SMN1; SMN2RAB9A | |
| SCHEMBL10260440 | 0.91 | ATM (0.36) | ATMSMN1; SMN2RAB9ALMNAALDH1A1 | |
| SCHEMBL10260872 | 0.88 | RAB9A (0.37) | ATMSMN1; SMN2RAB9ALMNAALDH1A1 | |
| SCHEMBL10293079 | 0.82 | FAAH (0.30) | ALDH1A1CES1 | |
| SCHEMBL10293080 | 0.81 | CYP1A2 (0.31) | ALDH1A1 | |
| SCHEMBL10293184 | 0.79 | CYP1A2 (0.31) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211891-B2 | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, DPP4, SPINT2 | ATM 4158/4885SPHK2 2189/4885SPHK1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.